ReviewChonnam medical journal2017
Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma.
Review in Chonnam medical journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04911998 (A Prospective Non Interventional Study on Targeted Therapy for Patients With Unresectable or Metastatic BRAFV600E Mutant Melanoma), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Non Interventional Study on Targeted Therapy for Patients With Unresectable or Metastatic BRAFV600E Mutant Melanoma
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- UV-Induced Somatic Mutations Driving Clonal Evolution in Healthy Skin, Nevus, and Cutaneous Melanoma.Life (Basel, Switzerland) · 2022Review
- Review
- In vivo assessment of the drug interaction between sorafenib and paracetamol in rats.Cancer chemotherapy and pharmacology · 2020Article
- Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1R.Oncogenesis · 2020Article
- Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy.Cancers · 2020Review
- Sorafenib sensitizes melanoma cells to vemurafenib through ferroptosis.Translational cancer research · 2020Article
- CaAdvances in cancer research · 2020Review
- β-Adrenoceptors as drug targets in melanoma: novel preclinical evidence for a role of βBritish journal of pharmacology · 2019Review
- Melanoma Cell Death Mechanisms.Chonnam medical journal · 2018Review
- Advances in Proteomic Techniques for Cytokine Analysis: Focus on Melanoma Research.International journal of molecular sciences · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma is one of the most aggressive cancers in the world and is responsible for the majority of skin cancer deaths. Recent advances in the field of immunotherapy using active, adoptive, and antigen-specific therapeutic approaches, have generated the expectation that these technologies have the potential to improve the treatment of advanced malignancies, including melanoma. Treatment options for metastatic melanoma patients have been dramatically improved by the FDA approval of new therapeutic agents including vemurafenib, dabrafenib, and sorafenib. These kinase inhibitors have the potential to work in tandem with MEK, PI3K/AKT, and mTOR to inhibit the activity of melanoma inducing BRAF mutations. This review summarizes the effects of the new therapeutic agents against melanoma and the underlying biology of these BRAF inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.